had a 99. 3 temperature; pain to the site of my injection; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date 2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose:1), for Covid-19 Immunization. The following information was reported: PYREXIA (non-serious) with onset 2021, outcome "unknown", described as "had a 99. 3 temperature"; VACCINATION SITE PAIN (non-serious) with onset 2021, outcome "unknown", described as "pain to the site of my injection". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: The patient received the second dose 3 weeks ago (as reported) and she was fully vaccinated now. The patient heard on the news that the booster shot is recommended for everyone now, is that true or is it just for the immune compromised she wanted to know and the response provided was that the Pfizer-BioNTech COVID-19 Vaccine is administered as a 2-dose series, 3 weeks apart, into the muscle. If you receive one dose of the Pfizer-BioNTech COVID-19 Vaccine, you should receive a second dose of this same vaccine 3 weeks later to complete the vaccination series.1If you are immunocompromised, you may receive a third dose of the Pfizer-BioNTech COVID-19 Vaccine at least 1 month after the second dose. Updated the emergency use authorizations for the Pfizer-BioNTech and Moderna COVID-19 vaccines to allow for the use of an additional dose in certain immunocompromised individuals. People who are fully vaccinated against COVID-19 and are not immunocompromised do not need an additional dose of COVID-19 vaccine at this time. She wanted to know how long is the Pfizer Vaccine good for, as they say it begins to drop after 6 months and response provided was on 01Apr2021, Pfizer and BioNTech announced an updated topline analysis up to 6 months following second dose of  Study. Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) is effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to 6 months after the second dose Vaccine was 100% effective in preventing severe disease as defined by the (CDC) and 95.3% effective in preventing severe disease as defined by the Vaccine was 100% effective in preventing COVID-19 cases in (country name redacted), where the B.1.351 lineage is prevalent to Vaccine safety now evaluated in more than 44,000 participants 16 years of age and older, with more than 12,000 vaccinated participants having at least six months follow-up after their second dose Pfizer and BioNTech plan to share these results  soon. Please note that the 'Pfizer-BioNTech COVID-19 Vaccine - Antibody Persistence and Duration of Immunity" has been updated to include the Press Release information.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.